The fiercest fight over the free market today might not be about wages or housing—but whether you should be allowed to sell your own kidney.
Story Snapshot
- Economists argue a regulated kidney market could wipe out waiting lists and save thousands of lives each year.
- Opponents warn that turning body parts into commodities shreds human dignity and targets the poor as “spare-part suppliers.”
- Nobel-winning research on “repugnant markets” shows moral disgust can overrule even life-saving efficiency gains.
- Iran’s controversial kidney-pay system and America’s no-cash kidney exchanges hint at very different futures for organ policy.
Why the Kidney Question Refuses to Go Away
Every year, people with failing kidneys sit tethered to dialysis machines, watching the transplant list move slower than the drip in their IV. Kidney transplantation is now the preferred treatment for end-stage renal disease, yet the United States bans buying or selling kidneys for transplantation.[2] The result is predictable: demand dwarfs supply, and some patients die waiting while healthy adults could, in principle, live perfectly well with one kidney.[1][2]
Economists look at that gap and see a textbook case of a blocked market. Alvin Roth, a Nobel Prize–winning economist, calls these “repugnant transactions”—trades some people want to make and others want to forbid.[2] Organ sales sit at the center of that category: the law says no, many ethicists say never, yet the raw numbers shout that a regulated market might save more lives than any new pill or machine.[1][2]
The Efficiency Argument: Lives, Dollars, and the Iran Experiment
Pro-market advocates start with a blunt claim: if you pay people to give up a kidney, more people will step forward, the waiting list shrinks, and fewer Americans die.[1] One analysis argues that compensating donors could eliminate the kidney shortfall and save taxpayers billions by reducing long-term dialysis costs, since transplantation is cheaper and more effective over time.[1] For readers with conservative instincts, that pairing—fewer deaths and less government spending—lands with obvious appeal.
Supporters point to Iran as the controversial proof-of-concept. Since the late 1980s, Iran has run a government-managed system where living kidney donors receive fixed compensation, and advocates claim the country essentially cleared its waiting list for kidneys.[1] Iran’s model is far from a libertarian free-for-all; it uses regulated prices and official matching rather than back-alley brokers. Proponents argue a U.S. version, built with tighter oversight, could capture the lifesaving benefits without importing Iran’s political baggage.[1]
https://twitter.com/irishpatriot91/status/2035558312209453425
The Moral Wall: Dignity, Exploitation, and Who Really Sells
Critics reply that this is not the same as paying someone to mow a lawn. A leading bioethics article notes that kidney markets are widely prohibited because they are assumed to undermine the seller’s dignity, reducing a human body to a parts catalog. When the typical seller is poor and desperate, payment stops looking like freedom and starts looking like coercion—“choice” under the shadow of rent, debt, or hunger rather than real autonomy.[5]
Law and ethics commentators warn that, in practice, organ markets tend to funnel organs from the poor to the rich.[1][5] That means the burdens of risk fall on people with the fewest options, while the benefits cluster around those with the best insurance. From a conservative, rule-of-law perspective, this looks less like a clean market and more like a magnet for predatory intermediaries, transplant tourism, and cross-border abuse—the very abuses the World Health Organization and others have urged countries to stamp out.[1]
Repugnant Markets: Why Common Sense Balks at “Efficient” Deals
Roth’s work on repugnant markets shows that many societies draw bright red lines around certain trades, even when everyone “consenting” seems to gain on paper.[2] Slavery, child labor, and selling votes are the classic examples. You could, in theory, create a “regulated auction” for each of these, but most Americans would rightly view that as a moral horror, not a clever efficiency fix. Organ sales sit on this frontier: not yet unthinkable to everyone, but viscerally offensive to many.[5]
Research on moral repugnance in the kidney debate finds that objections drop somewhat when people are forced to confront the cost of prohibition in lives lost and dollars spent.[1][3] Still, that shift does not erase the core discomfort with body-part markets; it only shows that some citizens are willing to tolerate a policy they find ugly if the human cost of keeping the ban climbs high enough. That is a grim calculus, not a ringing endorsement of commodifying organs.[1][3][5]
Middle Roads: Kidney Exchanges, Reimbursement, and Conservative Guardrails
Policymakers have already embraced some workarounds that increase transplants without crossing the line into cash-for-kidneys. Kidney exchange programs match incompatible donor–recipient pairs so each donor gives to a stranger, and each recipient receives a compatible kidney, all without money changing hands.[4] These exchanges, designed by economists like Roth, have expanded the number of transplants and attracted almost no moral backlash, precisely because they preserve the gift ethic.[4]
Other reforms reimburse donors for lost wages, travel, and childcare so that donating does not become an expensive act of charity.[3][4] This approach treats donors as citizens performing a public service, not vendors in a body-parts bazaar, and it aligns more closely with American conservative values: personal responsibility, respect for the body, and targeted relief from needless bureaucratic burdens. The open question is whether these tools can close the gap, or whether lawmakers will eventually face the hard choice of allowing some form of direct compensation for kidneys.[1]
Sources:
[1] Web – Should You Be Allowed To Sell a Kidney? Economist Explains ‘Repugnant …
[2] Web – Understanding moral repugnance: The case of the US market for …
[3] Web – [PDF] Repugnance as a Constraint on Markets – NBER
[4] Web – Consideration of Costs Can Reduce Moral Objections to Human …
[5] Web – Repugnant Markets and How They Get That Way – Baker Library